Status and features of vitamin D metabolism in obesity and its treatment

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In recent years, there has been significant interest in the role of adipose tissue in determining the bioavailability of vitamin D, which is attributable to the well-known inverse correlation between obesity and serum 25-hydroxyvitamin D concentrations, described for all age groups, nationalities, places of residence, and independent of gender. Screening studies show that obesity is inferior to low sun exposure as a predictor of vitamin D deficiency severity, while the prevalence of obesity has already reached global pandemic proportions and is observed in about 39% of the world’s adult population. Obesity has been shown to be associated with increased mortality due to its association with comorbidities, including type 2 diabetes mellitus (DM2), arterial hypertension, dyslipidemia, osteoarthritis, and sleep apnea. At the same time, both at the physiological and biochemical levels, the active form of vitamin D has been shown to have many effects that counteract the adverse effects of obesity, which may reduce the risks of tissue damage in obesity and associated metabolic disorders, such as DM2 and cardiovascular diseases. Treatment of obesity, including bariatric surgery, does not always lead to favorable changes in the status and action of vitamin D, which must be taken into account in clinical practice.

Full Text

Restricted Access

About the authors

Ekaterina A. Pigarova

National Medical Research Center of Endocrinology

Author for correspondence.
Email: kpigarova@gmail.com
ORCID iD: 0000-0001-6539-466X
SPIN-code: 6912-6331
Scopus Author ID: 55655098500

Dr. Sci. (Med.), Director of the Institute of Higher and Additional Professional Education, Leading Researcher at the Department of Neuroendocrinology

Russian Federation, Moscow

Larisa K. Dzeranova

National Medical Research Center of Endocrinology

Email: dzeranovalk@yandex.ru
ORCID iD: 0000-0002-0327-4619
SPIN-code: 2958-5555

Dr. Sci. (Med.), Scientific Secretary, Chief Researcher, Department of NeuroendocrinologyNational Research Center of Endocrinology, Moscow

Russian Federation, Moscow

References

  1. World Health Organization. Fact Sheet: Obesity and Overweight. Geneva, Switzerland: World Health Organization; 2016. URL: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
  2. Пигарова Е.А., Дзеранова Л.К. Ожирение, сахарный диабет и витамин D. Ожирение и метаболизм. 2024;21(3):316–324 doi: 10.14341/omet13161. [Pigarova E.A., Dzeranova L.K. Obesity, diabetes and vitamin D. Obesity and metabolism. 2024;21(3):316–324. (In Russ.)]. doi: 10.14341/omet13161.
  3. Saponaro F., Saba A., Zucchi R. An Update on Vitamin D Metabolism. Int J Mol Sci. 2020;21(18):6573. doi: 10.3390/ijms21186573.
  4. Пигарова Е.А., Рожинская Л.Я., Белая Ж.Е. и др. Клинические рекомендации Российской ассоциации эндокринологов по диагностике, лечению и профилактике дефицита витамина D у взрослых. Проблемы Эндокринологии. 2016;62(4):60–84. doi: 10.14341/probl201662460-84. [Pigarova E.A., Rozhinskaya L.Y., Belaya J.E. et al. Russian Association of Endocrinologists recommendations for diagnosis, treatment and prevention of vitamin D deficiency in adults. Problems of Endocrinology. 2016;62(4):60–84. (In Russ.)]. doi: 10.14341/probl201662460-84.
  5. Пигарова Е.А., Дзеранова Л.К., Яценко Д.А. Витамин D – вопросы всасывания и метаболизма в норме и при заболеваниях желудочно-кишечного тракта. Ожирение и метаболизм. 2022;19(1):123–133. doi: 10.14341/omet12835. [Pigarova E.A., Dzeranova L.К., Yatsenko D.A. Absorption and metabolism of vitamin D in health and in gastrointestinal tract diseases. Obesity and metabolism. 2022;19(1):123–133. (In Russ.)]. doi: 10.14341/omet12835.
  6. Carlberg C. Nutrigenomics of Vitamin D. Nutrients. 2019;11(3):676. doi: 10.3390/nu11030676.
  7. Szymczak-Tomczak A., Ratajczak A.E., Kaczmarek-Ryś M. et al. Pleiotropic Effects of Vitamin D in Patients with Inflammatory Bowel Diseases. J Clin Med. 2022;11(19):5715. doi: 10.3390/jcm11195715.
  8. Marazziti D., Parra E., Palermo S. et al. Vitamin D: A Pleiotropic Hormone with Possible Psychotropic Activities. Curr Med Chem. 2021;28(19):3843–3864. doi: 10.2174/0929867328666201210104701.
  9. Haussler M.R., Jurutka P.W., Mizwicki M., Norman A.W. Vitamin D receptor (VDR)-mediated actions of 1α,25(OH)2vitamin D3: Genomic and non-genomic mechanisms. Best Practice & Research Clinical Endocrinology & Metabolism. 2011;25(4):543–559. doi: 10.1016/j.beem.2011.05.010
  10. Davies M., Mawer E.B., Krawitt E.L. Comparative absorption of vitamin D3 and 25-hydroxyvitamin D3 in intestinal disease. Gut. 1980;21:287–92.
  11. Grossmann R.E., Tangpricha V. Evaluation of vehicle substances on vitamin D bioavailability: a systematic review. Mol Nutr Food Res. 2010 Aug;54(8):1055-61. doi: 10.1002/mnfr.200900578.
  12. Denker A.E., Lazarus N., Porras A. et al. Bioavailability of alendronate and vitamin D3 in an alendronate/vitamin D3 combination tablet. J Clin Pharmacol. 2011;51:1439–1448. doi: 10.1177/0091270010382010.
  13. Armas L.A., Hollis B.W., Heaney R.P. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 2004;89:5387–5391. doi: 10.1210/jc.2004-0360.
  14. Borel P., Caillaud D., Cano N.J. Vitamin D bioavailability: state of the art. Crit Rev Food Sci Nutr. 2015;55(9):1193–205. doi: 10.1080/10408398.2012.688897.
  15. Sitrin M.D., Pollack K.L., Bolt M.J., Rosenberg I.H. Comparison of vitamin D and 25-hydroxyvitamin D absorption in the rat. Am J Physiol Gastrointest Liver Physiol. 1982;242:G326–332. doi: 10.1152/ajpgi.1982.242.4.G326.
  16. Goncalves A., Gleize B., Bott R. et al. Phytosterols can impair vitamin D intestinal absorption in vitro and in mice. Mol Nutr Food Res. 2011;55(suppl 2):S303–S311. doi: 10.1002/mnfr.201100055.
  17. Silva M.C., Furlanetto T.W. Intestinal absorption of vitamin D: a systematic review, Nutrition Reviews. 2018;76(1):60–76. doi: 10.1093/nutrit/nux034.
  18. Charoenngam N., Kalajian T.A., Shirvani A. et al. A pilot-randomized, double-blind crossover trial to evaluate the pharmacokinetics of orally administered 25-hydroxyvitamin D3 and vitamin D3 in healthy adults with differing BMI and in adults with intestinal malabsorption. Am J Clin Nutr. 2021;114(3):1189–1199. doi: 10.1093/ajcn/nqab123.
  19. Blum M., Dolnikowski G., Seyoum E. et al. Vitamin D(3) in fat tissue. Endocrine. 2008;33(1):90–94. doi: 10.1007/s12020-008-9051-4.
  20. Wortsman J., Matsuoka L.Y., Chen T.C. et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000;72(3):690–693. doi: 10.1093/ajcn/72.3.690.
  21. Nguyen V.T., Li X., Elli E.F. et al. Vitamin D, inflammation, and relations to insulin resistance in premenopausal women with morbid obesity. Obesity (Silver Spring). 2015;23:1591–1597. doi: 10.1002/oby.21131.
  22. Clemente-Postigo M., Munoz-Garach A., Serrano M. et al. Serum 25-hydroxyvitamin D and adipose tissue vitamin D receptor gene expression: relationship with obesity and type 2 diabetes. J Clin Endocrinol Metab. 2015;100:E591–E595. doi: 10.1210/jc.2014-3016.
  23. Lu S., Cao Z.B. Interplay between vitamin D and adipose tissue: implications for adipogenesis and adipose tissue function. Nutrients. 2023;15(22):4832. doi: 10.3390/nu15224832.
  24. Nimitphong H., Holick M.F., Fried S.K., Lee M.J. 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 promote the differentiation of human subcutaneous preadipocytes. PLoS One. 2012;7:e52171. doi: 10.1371/journal.pone.0052171.
  25. Wamberg L., Christiansen T., Paulsen S.K. et al. Expression of vitamin D-metabolizing enzymes in human adipose tissue - the effect of obesity and diet-induced weight loss. Int J Obes. 2013;37:651–657. doi: 10.1038/ijo.2012.112.
  26. Pereira-Santos M., Costa P.R., Assis A.M. et al. Obesity and vitamin D deficiency: a systematic review and meta-analysis. Obes Rev. 2015;16(4):341–349. doi: 10.1111/obr.12239.
  27. YaoY., Zhu L., He L. et al. A meta-analysis of the relationship between vitamin D deficiency and obesity. Int J Clin Exp Med. 2015;8(9):14977–14984. URL: https://e-century.us/files/ijcem/8/9/ijcem0011016.pdf
  28. Snijder M.B., van Dam R.M., Visser M. et al. Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women. J Clin Endocrinol Metab. 2005;90(7):4119–4123. doi: 10.1210/jc.2005-0216.
  29. Hultin H., Edfeldt K., Sundbom M., Hellman P. Left-shifted relation between calcium and parathyroid hormone in obesity. J Clin Endocrinol Metab. 2010;95(8):3973–3981. doi: 10.1210/jc.2009-2822.
  30. Pannu P.K., Zhao Y., Soares M.J. Reductions in body weight and percent fat mass increase the vitamin D status of obese subjects: a systematic review and metaregression analysis. Nutr Res. 2016;36(3):201–213. doi: 10.1016/j.nutres.2015.11.013.
  31. Zammouri J., Vatier C., Capel E. et al. Molecular and Cellular Bases of Lipodystrophy Syndromes. Front. Endocrinol. 2022;12:803189. doi: 10.3389/fendo.2021.803189.
  32. Einafshar N., Esparham A., Moghani M.S. et al. The impact of metabolic and bariatric surgery on diabetic kidney disease in patients with type 2 diabetes: a systematic review and meta-analysis. Obes Surg. 2024. doi: 10.1007/s11695-024-07612-8.
  33. Ершова Е.В., Трошина Е.А. Применение бариатрических операций при сахарном диабете 2 типа: в помощь практическому врачу. Ожирение и метаболизм. 2016;13(1):50–56. doi: 10.14341/omet2016150-56. [Ershova E.V., Troshina E.A. Use of bariatric surgery in patients with type 2 diabetes: help to the practitioner. Obesity and metabolism. 2016;13(1):50–56. (In Russ.)]. doi: 10.14341/omet2016150-56.
  34. Althumiri N.A., Bindhim N.F., Al-Rayes S.A., Alumran A. A systematic review exploring dietary behaviors, psychological determinants and lifestyle factors associated with weight regain after bariatric surgery. Healthcare (Basel). 2024;12(22):2243. doi: 10.3390/healthcare12222243.
  35. Peterson L.A., Zeng X., Caufield-Noll C.P. et al. Vitamin D status and supplementation before and after bariatric surgery: a comprehensive literature review. Surg Obes Relat Dis. 2016;12:693–702. doi: 10.1016/j.soard.2016.01.001.
  36. Johnson J.M., Maher J.W., DeMaria E.J. et al. The long-term effects of gastric bypass on vitamin D metabolism. Ann Surg. 2006;243:701–704. doi: 10.1097/01.sla.0000216773.47825.c1
  37. Авдеева В.А., Суплотова Л.А., Рожинская Л.Я. Влияние бариатрической хирургии на костный метаболизм: в фокусе витамин D. Ожирение и метаболизм. 2022;19(1):116–122. doi: 10.14341/omet12702. [Avdeeva V.A., Suplotova L.A., Rozhinskaya L.Y. Effects of bariatric surgery on bone metabolism: focusing on vitamin D. Obesity and metabolism. 2022;19(1):116–122. (In Russ.)]. doi: 10.14341/omet12702.
  38. Goldner W.S., Stoner J.A., Lyden E. et al. Finding the optimal dose of vitamin D fol- lowing Roux-en-Y gastric bypass: a prospective, randomized pilot clinical trial. Obes Surg. 2009;19:173–179. doi: 10.1007/s11695-008-9680-y.
  39. Carlin A.M., Rao D.S., Yager K.M. et al. Treatment of vitamin D depletion after Roux-en-Y gastric bypass: a randomized prospective clinical trial. Surg Obes Relat Dis. 2009;5:444–449. doi: 10.1016/j.soard.2008.08.004.
  40. Дедов И.И., Мельниченко Г.А., Мокрышева Н.Г. и др. Проект федеральных клинических рекомендаций по диагностике, лечению и профилактике дефицита витамина D. Остеопороз и остеопатии. 2021:24(4):4–26. doi: 10.14341/osteo12937. [Dedov I.I., Mel’nichenko G.A., Mokrysheva N.G., et al. Draft federal clinical practice guidelines for the diagnosis, treatment, and prevention of vitamin D deficiency. Osteoporosis and Bone Diseases. 2021;24(4):4–26. (In Russ.)]. doi: 10.14341/osteo12937.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Bionika Media